Gut microbiota, known as "unrecognized organs", is closely related to the occurrence and development of tumors. Cancer is thought to occur secondary to local chronic inflammation. And some bacteria, such as Helicobacter pylori, also have direct genotoxicity, changing intracellular signaling pathways and thus causing abnormal cell growth. Systemic intestinal dysbiosis may lead to cancer, and fecal microbiota transplantation (FMT) can be a new weapon in anti-cancer treatment.Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities. The investigators conducted a prospective, one-arm, open-label study on the efficacy and safety of WMT in the treatment of oncotherapy-related complications. This study aimed to exploring the therapeutic potential of WMT in the treatment of oncotherapy-related intestinal complications and improving the quality of life of patients.
1. Age ≥18 years old; 2. Diagnosed as malignant tumor; 3. Patients who underwent cancer-related treatment suffering from gastrointestinal symptoms(e.g., abdominal pain, diarrhea, abdominal distension, and difficulty defecating) occurred after standard tumor therapy (such as chemotherapy, radiation, immunotherapy, surgical treatment, etc.); 4. Estimated time of survival ≥ 3 months, and vital signs were stable); 5. Physically qualified and intended to undergo FMT;
1. Patients who were pregnant or nursing; 2. Patients who were unable or unwilling to undergo a gastroscopy or colonoscopy; 3. Patients with cardiopulmonary failure; 4. Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the previous week; 5. history of inflammatory bowel disease and intestinal symptoms unrelated to tumor treatment; 6.Serious uncontrolled diseases and acute infectious diseases；
Parallel
Washed Microbiota Transplantation (WMT)
Other interventionWashed microbiota suspension delivered through mid-gut and lower-gut
Scores of gastrointestinal symptoms
Gastrointestinal symptoms will be evaluated according to NCI-CTC 5.0
Stool frequency and consistency
Stool frequency and consistency will be evaluated according to The Bristol Stool Form Scale (BSFS).
Adverse events
New onset of symptoms and the exacerbation of previous symptoms were recorded as adverse events (AEs)
Karnofsky Performance Status (KPS) scale
Changes in functional status of patients will be assessed according to the Karnofsky Performance Status (KPS) scale (ranging from 0 \[dead\] to 100 \[normal activity, no evidence of disease\])
Click on the lead sponsor to view all of their trials.
